NCT06770452 2025-09-23
HRS-4642 With Nimotuzumab and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer Patients
Zhejiang University
Phase 2 Recruiting
Clinical Trials
8 trialsNCT06389760 2024-10-31
Nimotuzumab Combined With mFOLFIRINOX/GX as Postoperative Adjuvant Therapy in Pancreatic Cancer
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2 Recruiting
NCT06409429 2024-05-10
Nimotuzumab Combined With GX as Postoperative Adjuvant Therapy in Pancreatic Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2/3 Not yet recruiting
NCT06404840 2024-05-08
Evaluating Nimotuzumab in Combination With AG Regimen for Pancreatic Cancer With Liver Metastases : A Prospective, Single-Arm, Phase II Study
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Recruiting
NCT06405685 2024-05-08
Nimotuzumab Plus AG in Pancreatic Cancer With Liver Metastasis
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT02395016 2024-04-04
A Study of Nimotuzumab Combinated With Gemcitabine in K-RAS Wild-type Locally Advanced and Metastatic Pancreatic Cancer
Biotech Pharmaceutical Co., Ltd.
Phase 3 Completed
NCT02945267 2016-10-26
Nimotuzumab Plus S1 Versus Placebo Plus S1 as Maintenance Treatment in Patients With Unresectable Pancreatic Cancer
Chinese PLA General Hospital
Phase 4 Unknown
NCT00561990 2015-10-15
Nimotuzumab in Adults With Pancreatic Cancer
Oncoscience AG
Phase 2/3 Completed